CTLA4 and neoplasm: The anti-PD-1 and anti-PDL-1 antibodies exhibit synergistic activity in preventing CTLA-4-mediated downregulation, reducing T-cell apoptosis and increasing the net activity of activated T-cells against tumor cells.